Establishing an Information Provision System in Response to the Guidelines for the Provision of Information in Sales Activities
First written in FY2020. 4 of 6 entries say "Restated". Latest entry: FY2024.
1 other company's latest entry also says "Restated".
- FY2024RestatedAnnual report
「The primary issues are to continue launching distinctive new drugs that meet medical needs, establish and maintain a system capable of providing a stable supply of high-quality products, and establish a sales structure through appropriate information provision so that the right patients receive appropriate prescriptions.」
The Company has reaffirmed the establishment of appropriate pharmaceutical information provision and a sales structure as key issues for stable growth. - FY2023-Q3RestatedAnnual report
「Amid the COVID-19 pandemic, the Company promoted hybrid medical information activities that effectively combined its traditional face-to-face meetings with various digital content, contributing to higher sales of Beova tablets, a treatment for overactive bladder, and darbepoetin alfa BS injection JCR, a treatment for renal anemia, among others. In addition, higher technical-fee revenue, export revenue, and co-promotion fees resulted in higher revenue overall.」
The Company continued to promote hybrid medical information activities combining face-to-face meetings with digital content. - FY2023-Q2RestatedAnnual report
「Amid the COVID-19 pandemic, the Company promoted hybrid medical information activities that effectively combined its traditional face-to-face meetings with various digital content, which contributed to higher sales of Beova tablets, a treatment for overactive bladder, and darbepoetin alfa BS injection JCR, a treatment for renal anemia, among others.」
The Company has reaffirmed its continued promotion of hybrid medical information activities combining face-to-face meetings with digital content. - FY2023-Q1AdvancedAnnual report
「Amid the COVID-19 pandemic, the Company promoted hybrid medical information activities that effectively combined its traditional face-to-face meetings with various digital content.」
The Company gave concrete form to hybrid medical information activities by combining its traditional face-to-face meetings with digital content. - FY2022RestatedAnnual report
「In addition to the Guidelines for Provision of Sales Information applicable from April 2019 and the response to COVID-19, promotional activities by pharmaceutical companies require the rapid establishment of a new pharmaceutical information-provision structure.」
In addition to responding to the Guidelines for Provision of Sales Information, the Company continues to identify the establishment of an information-provision structure, including measures addressing COVID-19, as an issue. - FY2020First statedAnnual report
「Promotional activities by pharmaceutical companies have been more strictly regulated under the Guidelines for Provision of Sales Information that took effect in April 2019, creating a need to rapidly establish a new structure for providing pharmaceutical information.」
For the first time, the Company separately identified the rapid establishment of a new pharmaceutical information-provision structure as an issue in response to the Guidelines for Provision of Sales Information applicable from April 2019.